Skip to main content

Table 3 Effects on outcomes after six and 12 months of follow-up for both treatment groups according to the intention-to-treat principle, boys only

From: One-year effects of two intensive inpatient treatments for severely obese children and adolescents

 

Short-stay

Long-stay

Crude

Adjusted

Mean (SD)

Mean (SD)

Beta (95 % CI)

Beta (95 % CI)

Primary outcome measure

SDS-BMI

 Baseline

3.7 (0.4)

3.7 (0.4)

  

 6-months

3.4 (0.6)

3.1 (0.7)

0.25 (−0.03; 0.52)

0.23 (−0.07; 0.53)

 12-months

3.4 (0.7)

2.9 (0.8)

0.34 (−0.09; 0.77)

0.31 (−0.14; 0.76)

 Overall effecta

  

0.25 (−0.15; 0.64)

0.26 (−0.15; 0.67)

Secondary outcomes

SDS-waist circumference

 Baseline

3.5 (0.4)

3.3 (0.3)

  

 6-months

3.0 (0.7)

2.6 (0.6)

0.10 (−0.35; 0.55)

0.05 (−0.39; 0.48)

 12-months

3.0 (1.0)

2.4 (0.9)

0.12 (−0.48; 0.72)

0.01 (−0.57; 0.60)

 Overall effecta

  

0.40 (−0.03; 0.83)

0.40 (−0.06; 0.86)

Systolic blood pressure (mmHg)

 Baseline

124.3 (15.0)

125.1 (14.0)

  

 6-months

122.0 (18.7)

120.2 (11.9)

3.34 (−5.35; 12.03)

4.31 (−3.56; 12.19)

 12-months

122.1 (12.3)

123.3 (14.4)

−1.46 (−9.12; 6.20)

0.45 (−6.74; 7.64)

 Overall effecta

  

0.52 (−9.22; 10.25)

2.04 (−8.27; 12.36)

Diastolic blood pressure (mmHg)

 Baseline

77.7 (11.0)

80.9 (9.2)

  

 6-months

64.4 (8.0)

68.2 (10.0)

−1.61 (−8.46; 5.24)

−2.91 (−9.17; 3.35)

 12-months

69.4 (8.3)

66.5 (11.7)

5.28 (−0.21; 10.76)

3.86 (−2.23; 9.94)

 Overall effecta

  

−0.73 (−7.66, 4.06)

−1.80 (−7.66, 4.06)

Fasting insulin (μU/L)

 Baseline

15.3 (7.7)

16.2 (13.2)

  

 6-months

12.4 (12.6)

11.8 (11.0)

0.78 (−4.44; 6.00)

0.73 (−4.54; 6.00)

 12-months

11.1 (5.8)

14.4 (13.8)

−0.82 (−4.84; 3.20)

−1.15 (−5.06; 2.76)

 Overall effecta

  

−0.58 (−7.69; 6.53)

0.14 (−6.93; 7.22)

2 h-insulin (μU/L)

 Baseline

75.4 (50.2)

53.3 (34.6)

  

 6-months

64.5 (68.2)

38.6 (20.2)

13.21 (−21.43; 47.84)

14.30 (−18.69; 47.29)

 12-months

65.1 (41.3)

62.7 (33.8)

2.81 (−14.94; 20.56)

3.47 (−16.01; 22.96)

 Overall effecta

  

21.31 (−7.19; 49.81)

22.60 (−5.09; 50.30)

Fasting glucose (mmol/L)

 Baseline

4.6 (0.2)

4.8 (0.4)

  

 6-months

4.8 (0.3)

4.7 (0.3)

0.14 (−0.05; 0.34)

0.14 (−0.05; 0.34)

 12-months

4.7 (0.3)

5.0 (0.2)

−0.16 (−0.36; 0.04)

−0.17 (−0.36; 0.02)

 Overall effecta

  

−0.14 (−0.31; 0.03)

−0.10 (−0.25; 0.06)

2 h-glucose (mmol/L)

 Baseline

6.3 (1.1)

5.7 (0.9)

  

 6-months

5.7 (1.5)

4.9 (0.9)

0.43 (−0.47; 1.33)

0.48 (−0.39; 1.34)

 12-months

5.6 (0.9)

6.0 (1.1)

−0.40 (−1.06; 0.27)

−0.43 (−1.14; 0.29)

 Overall effecta

  

0.42 (−0.26; 1.10)

0.49 (−0.25; 1.23)

HDL-cholesterol (mmol/L)

 Baseline

1.1 (0.3)

1.0 (0.2)

  

 6-months

1.1 (0.4)

1.1 (0.2)

−0.08 (−0.18; 0.13)

−0.08 (−0.19; 0.03)

 12-months

1.2 (0.5)

1.2 (0.4)

−0.08 (−0.27; 0.11)

−0.07 (−0.28; 0.15)

 Overall effecta

  

0.05 (−0.17; 0.28)

0.08 (−0.13; 0.29)

Triglycerides (mmol/L)

 Baseline

1.0 (0.5)

1.2 (0.7)

  

 6-months

1.1 (0.7)

1.1 (0.7)

0.13 (−0.30, 0.56)

0.06 (−0.31, 0.44)

 12-months

1.4 (0.9)

1.4 (0.9)

−0.06 (−0.51, 0.63)

−0.04 (−0.56, 0.48)

 Overall effecta

  

−0.10 (−0.56, 0.36)

−0.10 (−0.52, 0.33)

HOMA-IR

 Baseline

3.1 (1.5)

3.5 (3.0)

  

 6-months

2.7 (2.7)

2.5 (2.4)

0.40 (−0.77; 1.58)

0.37 (−0.80; 1.54)

 12-months

2.3 (1.2)

3.3 (3.3)

−0.17 (−1.05, 0.72)

−0.27 (−1.12, 0.59)

 Overall effecta

  

−0.30 (−1.87; 1.28)

−0.12 (−1.68; 1.44)

  1. Adjusted models corrected for baseline, ethnicity, and socio economic status
  2. Abbreviations: CI confidence interval, SD standard deviation, SDS-BMI standard deviation of body mass index, SDS-waist circumference standard deviation of waist circumference, HDL high-density lipoprotein, HOMA-IR homeostasis model assessment for insulin resistance
  3. aOverall effect can be interpreted as the average difference over time between the two treatment groups